NCT05774756Phase 3Active not recruiting

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-03-18Actual
Enrollment · participants143Actual
Source updated2026-08-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean % change in BMI. After: Measure: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 120 participants (planned). After: 143 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview